Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms"
Neuroendocrinology. 2020;110(1-2):158-160.
doi: 10.1159/000503999.
Epub 2019 Oct 10.
1 First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, lefterchatz@gmail.com.
2 251 HAF and VA Hospital, Athens, Greece, lefterchatz@gmail.com.
3 First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
4 Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
5 Department of Clinical Oncology and Radiotherapy, Medical University of Silesia, Katowice, Poland.
6 Oncology Department and Radiation Therapy Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
7 Neuroendocrine Tumor Unit, Department of Endocrinology and Metabolism, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
8 Department of Endocrinology and Neuroendocrine Neoplasms, Medical University of Silesia, Katowice, Poland.
9 Department of Endocrinology and Neuroendocrine Tumors, Medical University of Silesia, Katowice, Poland.
10 Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.
11 Hematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon University General Hospital, National and Kapodistrian University of Athens, Athens, Greece.